Hans Gelderblom

Leiden University Medical Center

Research Interests

Explore related searches

Contact this professor

Google Scholar

Recent Grants

Grant: Close

Open Date: 2023-01-01

Close Date: 2024-12-01

Articles (20)

Collaborators (19)

Emanuela Palmerini

University of Toronto

Nicholas M. Bernthal

UNITED STATES

MARTA SPREAFICO

Assistant Professor

Leiden University

Margaret von Mehren

Fox Chase Cancer Center

UNITED STATES

Winette van der Graaf

The Netherlands Cancer Institute

Judith Bovee

professor of pathology

Leiden University

John R. Zalcberg

Karoly Szuhai

Associate Professor

Michiel A. J. van de Sande

John Healey

Chief of Orthopaedic Surgery

Memorial Sloan Kettering Cancer Center

UNITED STATES

Henk-Jan Guchelaar

Leiden University Medical Center

VINOD RAVI

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Piotr Rutkowski

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

David Creytens

Sebastian Bauer

Professor / Chair

Universität Duisburg-Essen

Anna Reyners

Professor in Palliative Medicine

University Medical Center Groningen

Jean-Yves Blay

University Professor, Medical Oncology

Université Claude Bernard Lyon 1 - Domaine de Rockefeller

R. Lor Randall

UNITED STATES

Jesse Swen

Full professor of clinical pharmacy, in particular translational pharmacogenetics

Leiden University Medical Center

Hans Gelderblom

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (20)

A Genome‐Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early‐Stage Breast Cancer Patients

Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study

MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Machine Learning versus Cox Models for Predicting Overall Survival in Patients with Osteosarcoma: A Retrospective Analysis of the EURAMOS-1 Clinical Trial Data

Dynamic Prediction of Overall Survival for Patients with Osteosarcoma: A Retrospective Analysis of the EURAMOS-1 Clinical Trial Data

Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population

The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)

Financial difficulties experienced by patients with gastrointestinal stromal tumours (GIST) in the Netherlands: data from a cross-sectional multicentre study

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies.

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies

A novel colony‐stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor

UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety

Association between local treatment modalities and event-free survival, overall survival, and local recurrence in patients with localised Ewing Sarcoma. Report from the Ewing 2008 trial

The MOTION study: a randomized, Phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation.

Evaluation of response to neoadjuvant chemotherapy in osteosarcoma using dynamic contrast-enhanced MRI: development and external validation of a model.

Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study

Collaborators (19)

Emanuela Palmerini

Nicholas M. Bernthal

MARTA SPREAFICO

Margaret von Mehren

Winette van der Graaf

Judith Bovee

John R. Zalcberg

Karoly Szuhai

Michiel A. J. van de Sande

John Healey

Henk-Jan Guchelaar

VINOD RAVI

Piotr Rutkowski

David Creytens

Sebastian Bauer

Anna Reyners

Jean-Yves Blay

R. Lor Randall

Jesse Swen

How do I reach out?

Meet Kite AI